MBD4 Polyclonal Antibody Catalog Number:11270-1-AP Featured Product 2 Publications

Total Page：16

File Type：pdf, Size：1020Kb

For Research Use Only MBD4 Polyclonal antibody Catalog Number:11270-1-AP Featured Product 2 Publications www.ptglab.com Catalog Number: GenBank Accession Number: Purification Method: Basic Information 11270-1-AP BC011752 Antigen affinity purification Size: GeneID (NCBI): Recommended Dilutions: 150ul , Concentration: 160 μg/ml by 8930 WB 1:500-1:1000 Nanodrop and 133 μg/ml by Bradford Full Name: method using BSA as the standard; methyl-CpG binding domain protein 4 Source: Calculated MW: Rabbit 66 kDa Isotype: Observed MW: IgG 66 kDa Immunogen Catalog Number: AG1822 Applications Tested Applications: Positive Controls: WB,ELISA WB : human skin tissue, A549 cells Cited Applications: WB Species Specificity: human Cited Species: human MBD4, also named as MED1, is a 580 amino acid protein, which Interacts with MLH1. MBD4 as a mismatch-specific Background Information DNA N-glycosylase is involved in DNA repair and has thymine glycosylase activity and is specific for G:T mismatches within methylated and unmethylated CpG sites. MBD4 can also remove uracil or 5-fluorouracil in G:U mismatches. MBD4 exists some isoforms with MV 66 kDa and 30 kDa (The identification of a novel alternatively spliced form of the MBD4 DNA glycosylase). Notable Publications Author Pubmed ID Journal Application Xiao-Hui Wang 34103526 Nat Commun WB Mei-Rong Liang 31313936 Genet Test Mol Biomarkers WB Storage: Storage Store at -20°C. Stable for one year after shipment. Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3. Aliquoting is unnecessary for -20ºC storage For technical support and original validation data for this product please contact: This product is exclusively available under Proteintech T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free E: [email protected] Group brand and is not available to purchase from any in USA), or 1(312) 455-8498 (outside USA) W: ptglab.com other manufacturer. Selected Validation Data human skin tissue were subjected to SDS PAGE followed by western blot with 11270-1-AP (MBD4 antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours..

Copy Link

Recommended publications

Developmental Delay and the Methyl Binding Genes H Turner, F Macdonald, S Warburton, F Latif, T Webb
1of3 ELECTRONIC LETTER J Med Genet: first published as 10.1136/jmg.40.2.e13 on 1 February 2003. Downloaded from Developmental delay and the methyl binding genes H Turner, F MacDonald, S Warburton, F Latif, T Webb ............................................................................................................................. J Med Genet 2003;40:e13(http://www.jmedgenet.com/cgi/content/full/40/2/e13) he report by Amir et al1 that Rett syndrome (RS) is associ- children referred with a clinical diagnosis of Angelman ated with mutations in the MECP2 gene permitted labora- syndrome (AS) but without an abnormality in 15q11q13 tory diagnosis of this devastating yet common neurode- showed that 4/46 of the girls in one case8 and 5/40 in the T 9 velopmental disorder. Hitherto the paucity of familial cases of other actually had Rett syndrome. Of these nine probands, the syndrome and the failure to identify the syndrome in only one was later found to have a clinical presentation incon- males despite fairly wide clinical criteria had deﬁned it as an sistent with the laboratory diagnosis. This may not be surpris- X linked dominant disorder with male lethality.2 Soon, ing given that in very small girls the two syndromes may however, reports from the few families in which RS is present with overlapping clinical features and so be difﬁcult to segregating showed that male family members who inherited differentiate on clinical grounds alone. the same mutation in the MECP2 gene as their affected female Familial cases of developmental handicap
[Show full text]
Epigenetic Regulation of DNA Repair Genes and Implications for Tumor Therapy ⁎ ⁎ Markus Christmann , Bernd Kaina
Mutation Research-Reviews in Mutation Research xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Mutation Research-Reviews in Mutation Research journal homepage: www.elsevier.com/locate/mutrev Review Epigenetic regulation of DNA repair genes and implications for tumor therapy ⁎ ⁎ Markus Christmann , Bernd Kaina Department of Toxicology, University of Mainz, Obere Zahlbacher Str. 67, D-55131 Mainz, Germany ARTICLE INFO ABSTRACT Keywords: DNA repair represents the first barrier against genotoxic stress causing metabolic changes, inflammation and DNA repair cancer. Besides its role in preventing cancer, DNA repair needs also to be considered during cancer treatment Genotoxic stress with radiation and DNA damaging drugs as it impacts therapy outcome. The DNA repair capacity is mainly Epigenetic silencing governed by the expression level of repair genes. Alterations in the expression of repair genes can occur due to tumor formation mutations in their coding or promoter region, changes in the expression of transcription factors activating or Cancer therapy repressing these genes, and/or epigenetic factors changing histone modifications and CpG promoter methylation MGMT Promoter methylation or demethylation levels. In this review we provide an overview on the epigenetic regulation of DNA repair genes. GADD45 We summarize the mechanisms underlying CpG methylation and demethylation, with de novo methyl- TET transferases and DNA repair involved in gain and loss of CpG methylation, respectively. We discuss the role of p53 components of the DNA damage response, p53, PARP-1 and GADD45a on the regulation of the DNA (cytosine-5)- methyltransferase DNMT1, the key enzyme responsible for gene silencing. We stress the relevance of epigenetic silencing of DNA repair genes for tumor formation and tumor therapy.
[Show full text]
Deficiency in DNA Mismatch Repair of Methylation Damage Is a Major
bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388108; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Deficiency in DNA mismatch repair of methylation damage is a major 2 mutational process in cancer 3 1 1 1 1 1,* 4 Hu Fang , Xiaoqiang Zhu , Jieun Oh , Jayne A. Barbour , Jason W. H. Wong 5 6 1School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of 7 Hong Kong, Hong Kong Special Administrative Region 8 9 *Correspondence: [email protected] 10 11 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.18.388108; this version posted November 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Abstract 2 DNA mismatch repair (MMR) is essential for maintaining genome integrity with its 3 deficiency predisposing to cancer1. MMR is well known for its role in the post- 4 replicative repair of mismatched base pairs that escape proofreading by DNA 5 polymerases following cell division2. Yet, cancer genome sequencing has revealed that 6 MMR deficient cancers not only have high mutation burden but also harbour multiple 7 mutational signatures3, suggesting that MMR has pleotropic effects on DNA repair. The 8 mechanisms underlying these mutational signatures have remained unclear despite 9 studies using a range of in vitro4,5 and in vivo6 models of MMR deficiency.
[Show full text]
Involvement of MBD4 Inactivation in Mismatch Repair-Deficient Tumorigenesis
Involvement of MBD4 inactivation in mismatch repair-deficient tumorigenesis The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Tricarico, R., S. Cortellino, A. Riccio, S. Jagmohan-Changur, H. van der Klift, J. Wijnen, D. Turner, et al. 2015. “Involvement of MBD4 inactivation in mismatch repair-deficient tumorigenesis.” Oncotarget 6 (40): 42892-42904. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26318553 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 40 Involvement of MBD4 inactivation in mismatch repair-deficient tumorigenesis Rossella Tricarico1, Salvatore Cortellino2, Antonio Riccio3, Shantie Jagmohan- Changur4, Heleen Van der Klift5, Juul Wijnen5, David Turner6, Andrea Ventura7, Valentina Rovella8, Antonio Percesepe9, Emanuela Lucci-Cordisco10, Paolo Radice11, Lucio Bertario11, Monica Pedroni12, Maurizio Ponz de Leon12, Pietro Mancuso1,13, Karthik Devarajan14, Kathy Q. Cai15, Andres J.P. Klein-Szanto15, Giovanni Neri10, Pål Møller16, Alessandra Viel17, Maurizio Genuardi10, Riccardo Fodde4, Alfonso Bellacosa1 1Cancer Epigenetics and Cancer Biology Programs, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States 2IFOM-FIRC Institute of Molecular Oncology, Milan,
[Show full text]
DNA Excision Repair Proteins and Gadd45 As Molecular Players for Active DNA Demethylation
Cell Cycle ISSN: 1538-4101 (Print) 1551-4005 (Online) Journal homepage: http://www.tandfonline.com/loi/kccy20 DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation Dengke K. Ma, Junjie U. Guo, Guo-li Ming & Hongjun Song To cite this article: Dengke K. Ma, Junjie U. Guo, Guo-li Ming & Hongjun Song (2009) DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation, Cell Cycle, 8:10, 1526-1531, DOI: 10.4161/cc.8.10.8500 To link to this article: http://dx.doi.org/10.4161/cc.8.10.8500 Published online: 15 May 2009. Submit your article to this journal Article views: 135 View related articles Citing articles: 92 View citing articles Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=kccy20 Download by: [University of Pennsylvania] Date: 27 April 2017, At: 12:48 [Cell Cycle 8:10, 1526-1531; 15 May 2009]; ©2009 Landes Bioscience Perspective DNA excision repair proteins and Gadd45 as molecular players for active DNA demethylation Dengke K. Ma,1,2,* Junjie U. Guo,1,3 Guo-li Ming1-3 and Hongjun Song1-3 1Institute for Cell Engineering; 2Department of Neurology; and 3The Solomon Snyder Department of Neuroscience; Johns Hopkins University School of Medicine; Baltimore, MD USA Abbreviations: DNMT, DNA methyltransferases; PGCs, primordial germ cells; MBD, methyl-CpG binding protein; NER, nucleotide excision repair; BER, base excision repair; AP, apurinic/apyrimidinic; SAM, S-adenosyl methionine Key words: DNA demethylation, Gadd45, Gadd45a, Gadd45b, Gadd45g, 5-methylcytosine, deaminase, glycosylase, base excision repair, nucleotide excision repair DNA cytosine methylation represents an intrinsic modifica- silencing of gene activity or parasitic genetic elements (Fig.
[Show full text]
Role of DNA Methyl-Cpg-Binding Protein Mecp2 in Rett Syndrome Pathobiology and Mechanism of Disease
biomolecules Review Role of DNA Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome Pathobiology and Mechanism of Disease Shervin Pejhan † and Mojgan Rastegar * Regenerative Medicine Program, and Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB R3E 0J9, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-(204)-272-3108; Fax: +1-(204)-789-3900 † Current Address: Neuropathology Program, Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C, Canada. Abstract: Rett Syndrome (RTT) is a severe, rare, and progressive developmental disorder with patients displaying neurological regression and autism spectrum features. The affected individuals are primarily young females, and more than 95% of patients carry de novo mutation(s) in the Methyl- CpG-Binding Protein 2 (MECP2) gene. While the majority of RTT patients have MECP2 mutations (classical RTT), a small fraction of the patients (atypical RTT) may carry genetic mutations in other genes such as the cyclin-dependent kinase-like 5 (CDKL5) and FOXG1. Due to the neurological basis of RTT symptoms, MeCP2 function was originally studied in nerve cells (neurons). However, later research highlighted its importance in other cell types of the brain including glia. In this regard, scientists beneﬁtted from modeling the disease using many different cellular systems and transgenic mice with loss- or gain-of-function mutations. Additionally, limited research in human postmortem brain tissues provided invaluable ﬁndings in RTT pathobiology and disease mechanism. MeCP2 expression in the brain is tightly regulated, and its altered expression leads to abnormal brain function, implicating MeCP2 in some cases of autism spectrum disorders.
[Show full text]
Reading Targeted DNA Damage in the Active
Reading targeted DNA damage in the active demethylation pathway: role of accessory domains of eukaryotic AP endonucleases and thymine-DNA glycosylases Alexander Popov, Inga Grin, Antonina Dvornikova, Bakhyt Matkarimov, Regina Groisman, Murat Saparbaev, Dmitry Zharkov To cite this version: Alexander Popov, Inga Grin, Antonina Dvornikova, Bakhyt Matkarimov, Regina Groisman, et al.. Reading targeted DNA damage in the active demethylation pathway: role of accessory domains of eukaryotic AP endonucleases and thymine-DNA glycosylases. Journal of Molecular Biology, Elsevier, 2020, 432 (6), pp.1747-1768. 10.1016/j.jmb.2019.12.020. hal-03060641 HAL Id: hal-03060641 https://hal.archives-ouvertes.fr/hal-03060641 Submitted on 14 Dec 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. *Manuscript Click here to view linked References Reading targeted DNA damage in the active demethylation 1 pathway: role of accessory domains of eukaryotic AP endonucleases 2 3 4 and thymine-DNA glycosylases 5 1 1,2 1,2 6 Alexander V. Popov , Inga R. Grin , Antonina P. Dvornikova
[Show full text]
The Thymine Glycosylase MBD4 Can Bind to the Product of Deamination at Methylated Cpg Sites DNA-Bound Structures and Mutants
letters to nature 13. Fuentes-Prior, P. et al. Structure of the thrombin complex with triabin, a lipocalin-like exosite-binding inhibits activation by the thrombomodulin-thrombin complex without affecting activation by free inhibitor derived from a triatomine bug. Proc. Natl Acad. Sci. USA 94, 11845±11850 (1997). thrombin. J. Biol. Chem. 271, 22285±22288 (1996). 14. Zushi, M. et al. Aspartic acid 349 in the fourth epidermal growth factor-like structure of human 28. Vincenot, A., Gaussem, P., Pittet, J. L., Debost, S. & Aiach, M. Amino acids 225-235** of the protein C thrombomodulin plays a role in its Ca2+-mediated binding to protein C. J. Biol. Chem. 266, 19886± serine-protease domain are important for the interaction with the thrombin-thrombomodulin 19889 (1991). complex. FEBS Lett. 367, 153±157 (1995). 15. Campbell, I. D. & Bork, P. Epidermal growth factor-like modules. Curr. Opin. Struct. Biol. 3, 385±392 29. Parry, M. A. et al. The ternary microplasmin-staphylokinase-microplasmin complex is a proteinase- (1993). cofactor-substrate complex in action. Nature Struct. Biol. 5, 917±923 (1998). 16. Downing, A. K. et al. Solution structure of a pair of calcium-binding epidermal growth factor-like 30. Leslie, A. in Crystal. Computing V (eds Moras, D., Podjarny, A. D. & Thierry, J. C.) 27±38 (Oxford domains: implications for the Marfan syndrome and other genetic disorders. Cell 85, 597±605 Univ. Press, Oxford, 1991). (1996). 31. Collaborative Computational Project No. 4. The CCP4 suite: programs for protein crystallography. 17. Knobe, K. E. et al. Probing the activation of protein C by the thrombin-thrombomodulin complex Acta Crystallogr.
[Show full text]
Mbd4 Inactivation Increases C3T Transition Mutations and Promotes Gastrointestinal Tumor Formation
Mbd4 inactivation increases C3T transition mutations and promotes gastrointestinal tumor formation Edmund Wong*, Kan Yang†‡, Mari Kuraguchi†‡, Uwe Werling*, Elena Avdievich*, Kunhua Fan†, Melissa Fazzari§, Bo Jin*, Anthony M. C. Brown†¶, Martin Lipkin†, and Winfried Edelmann*ʈ *Department of Cell Biology, §Biostatistics Core, Albert Einstein Cancer Center, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461; †Strang Cancer Research Laboratory at The Rockefeller University, New York, NY 10021; and ¶Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, NY 10021 Communicated by Matthew D. Scharff, Albert Einstein College of Medicine, Bronx, NY, September 23, 2002 (received for review August 8, 2002) Mbd4 (methyl-CpG binding domain 4) is a novel mammalian repair tion that MBD4 contained an endonuclease activity that can enzyme that has been implicated biochemically in the repair of convert supercoiled plasmid DNA into nicked, linear molecules, mismatched G-T residues at methylated CpG sites. In addition, the it was suggested that MBD4 could function in mammalian MMR human protein has been shown to interact with the DNA mismatch in a manner reminiscent of the MutH endonuclease in bacterial repair protein MLH1. To clarify the role of Mbd4 in DNA repair in MMR (9). However, additional biochemical studies using dou- vivo and to examine the impact of Mbd4 inactivation on gastro- ble-stranded oligonucleotide substrates failed to detect an intestinal (GI) tumorigenesis, we introduced a null mutation into MBD4 endonuclease activity and therefore did not support a the murine Mbd4 gene by gene targeting. Heterozygous and role of MBD4 in mammalian MMR strand discrimination (7).
[Show full text]
Depression Accelerates the Development of Gastric Cancer Through Reactive Oxygen Species‑Activated ABL1 (Review)
ONCOLOGY REPORTS 36: 2435-2443, 2016 Depression accelerates the development of gastric cancer through reactive oxygen species‑activated ABL1 (Review) TIANHE HUANG1, FULING ZHOU2, FENG WANG-JOHANNING3, KEJUN NAN1 and YONGCHANG WEI1,4 1Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061; 2Department of Clinical Hematology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China; 3Viral Oncology Program, SRI International, Menlo Park, CA 94025, USA; 4Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China Received May 10, 2016; Accepted September 5, 2016 DOI: 10.3892/or.2016.5127 Abstract. Depression is a common symptom among gastric 5. Conclusions cancer (GC) patients and serves as a potential indication of 6. Perspective poor prognosis and advanced cancer clinical stage. However, the molecular mechanism of depression-associated poor prognoses of GC patients remains unclear. Recent studies have 1. Introduction revealed that GC patients with depression are under high levels of oxidative stress (OS) status that is accompanied by the Despite the decline in the morbidity of gastric cancer (GC) dysfunction of numerous proto-oncogenes, including the ABL in recent years, GC remains the fourth most common cancer proto-oncogene 1 (ABL1), which is a non-receptor tyrosine and the second-leading cause of cancer-related death globally kinase. Recent evidence indicates that ABL1 was dysregu- with >700,000 human deaths per year (1,2). The occurrence lated in both major depressive disorder (MDD) and cancer of depression challenges cancer treatment and acts as an patients with depression, and high levels of reactive oxygen underlying indicator of advanced stages and poor prognoses species (ROS) can lead to the activation of ABL1 in response to of cancer patients (3).
[Show full text]
DNA Modifications and Neurological Disorders
Neurotherapeutics (2013) 10:556–567 DOI 10.1007/s13311-013-0223-4 REVIEW DNA Modifications and Neurological Disorders Yi-Lan Weng & Ran An & Jaehoon Shin & Hongjun Song & Guo-li Ming Published online: 25 September 2013 # The American Society for Experimental NeuroTherapeutics, Inc. 2013 Abstract Mounting evidence has recently underscored the Introduction importance of DNA methylation in normal brain functions. DNA methylation machineries are responsible for dynamic The methylation of cytosines at the 5-carbon position (5- regulation of methylation patterns in discrete brain regions. In methylcytosine; 5mC) in genomic DNA is a critical epigenetic addition to methylation of cytosines in genomic DNA mark in the metazoan genome. In multicellular organisms, cell (5-methylcytosine; 5mC), other forms of modified cytosines, type-specific landscapes of methylation patterns, the methylome, such as 5-hydroxymethylcytosine, 5-formylcytosine, and confer one of the bases for cell type-specific gene expression, 5-carboxylcytosine, can potentially act as epigenetic marks resulting in vastly diverse cellular phenotypes and functions out that regulate gene expression. Importantly, epigenetic modifi- of identical genetic materials. Moreover, DNA methylation plays cations require cognate binding proteins to read and translate important roles in genomic imprinting, X chromosome inactiva- information into gene expression regulation. Abnormal or tion, and maintenance of genomic stability [1]. Appropriate incorrect interpretation of DNA methylation patterns can
[Show full text]
Methylguanine-DNA Methyltransferase Gene Expression by Histone Acetylation and Methyl-Cpg Binding Proteins
Molecular Cancer Therapeutics 61 Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins Rebecca P. Danam, Sherie R. Howell, MGMT-silenced cells. Our findings implicate specific MBD Thomas P. Brent, and Linda C. Harris proteins in methylation-mediated transcriptional silencing of MGMT. [Mol Cancer Ther 2005;4(1):61–9] Department of Molecular Pharmacology, St. Jude Children’s Research Hospital, Memphis, Tennessee Introduction Abstract The DNA repair protein, O6-methylguanine-DNA methyl- Transcriptional silencing of the DNA repair gene, O6-methyl- transferase (MGMT), removes alkyl adducts from the guanine-DNA methyltransferase (MGMT) in a proportion of O6-position of guanine in DNA and protects cells against transformed cell lines is associated with methylated CpG the mutagenic, carcinogenic and cytotoxic effects of alkyl- hotspots in the MGMT 5V flank. The goal of the study was ating agents. MGMT is expressed in all human cells, to evaluate the mechanism by which CpG methylation tissues, and most tumors, although its expression varies of the MGMT promoter region influenced silencing of widely (1). Furthermore, MGMT is silenced in a significant the gene. Analysis of histone acetylation status in two proportion (f20-30%) of malignant and transformed cell regions of the promoter using chromatin immunopre- lines and a fraction of primary tumors. Such silenced cells cipitation assay showed that a higher level of histone are hypersensitive to cancer therapeutic and carcinogenic acetylation was associated with expression in three MGMT- alkylating agents (2). expressing cell lines (HeLa CCL2, HT29, and Raji) com- MGMT gene has a CpG-rich promoter containing a CpG pared with three MGMT-silenced cell lines (HeLa S3, BE, island with no TATA or CAAT boxes.
[Show full text]